About us
Liminatus Pharma is a pre‑clinical‑stage immuno‑oncology company pioneering the development of a second‑generation CD47‑blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first‑generation CD47 blockades. Building on more than a decade of CD47‑blockade immunotherapy development and clinical trial setbacks experienced by numerous bioventures, we engineered an upgraded CD47‑blockade antibody. The result—IBA101—is being advanced as a next‑generation immuno‑oncology therapy with broad applicability across a range of solid tumors.
Our mission is to develop novel immunotherapies that restore immune balance and broaden treatment options for cancer patients. We understand the human immune system as a finely tuned balance between innate and adaptive immunity—yet most approved immuno‑oncology drugs focus solely on enhancing T‑cell (adaptive) function, risking systemic imbalance. IBA101, our second‑generation CD47 blockade antibody, uniquely augments innate immunity. When combined with existing checkpoint inhibitors, it restores immune equilibrium to drive more effective, durable anti‑tumor responses. By reestablishing this balance, we aim to create safer, next‑generation therapies that transform outcomes for patients worldwide.